Cosmos Holdings Inc. Share Price OTC Markets
Stocks
COSM
US2214131078
Pharmaceuticals
OTC Markets Traded|
Delayed
OTC Markets
08:44:35 05/10/2021 pm IST
|
5-day change | 1st Jan Change | ||
| 4.510 USD | -5.65% |
|
-2.45% | - |
| 11/09 | Cosmos Health Unit Enters 5-Year Contract Manufacturing Deal With Viofar Over Cardiovascular Medicine | MT |
| 03/09 | Cosmos Health Inc. Reaffirms Earnings Guidance for the Year 2026, 2027 and 2029 | CI |
| Market Cap | 3.83Cr 3.36Cr 3.17Cr 2.89Cr 5.41Cr 367.18Cr 5.45Cr 38Cr 15Cr 186.87Cr 14Cr 14Cr 608.11Cr | P/E 2026 * |
-1.81x | P/E 2027 * | 5.43x |
|---|---|---|---|---|---|
| Enterprise Value | 3.83Cr 3.36Cr 3.17Cr 2.89Cr 5.41Cr 367.18Cr 5.45Cr 38Cr 15Cr 186.87Cr 14Cr 14Cr 608.11Cr | EV / Sales 2026 * |
0.47x | EV / Sales 2027 * | 0.35x |
| Free-Float |
76.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -5.65% |
| Manager | Title | Age | Since |
|---|---|---|---|
Grigorios Siokas
CEO | Chief Executive Officer | 60 | 26/02/2016 |
Georgios Terzis
DFI | Director of Finance/CFO | 43 | 11/11/2020 |
| Chief Operating Officer | 56 | 01/02/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 13/01/2014 | |
Grigorios Siokas
CHM | Chairman | 60 | 26/02/2016 |
John Hoidas
BRD | Director/Board Member | 59 | 18/11/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.65% | -2.45% | - | - | 3.83Cr | ||
| -1.27% | -1.16% | +14.30% | +98.19% | 10TCr | ||
| +0.61% | -1.64% | +44.02% | +150.25% | 5.15TCr | ||
| -0.39% | +0.78% | -14.33% | +267.14% | 2.08TCr | ||
| -0.25% | -0.87% | -11.20% | -10.55% | 793.36Cr | ||
| -1.66% | -0.34% | -38.67% | -34.93% | 680.43Cr | ||
| +2.80% | +5.40% | -1.23% | +15.38% | 652.4Cr | ||
| -0.20% | -0.93% | -19.00% | -33.12% | 593.28Cr | ||
| +0.33% | +1.41% | -2.13% | +20.63% | 494.52Cr | ||
| +1.25% | +8.76% | +20.44% | +22.78% | 401.98Cr | ||
| Average | -0.44% | +0.72% | -0.87% | +55.08% | 2.33TCr | |
| Weighted average by Cap. | -0.45% | -0.32% | +14.39% | +109.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.08Cr 7.11Cr 6.7Cr 6.11Cr 11Cr 775.62Cr 12Cr 80Cr 31Cr 394.75Cr 30Cr 30Cr 1.28TCr | 11Cr 9.75Cr 9.19Cr 8.38Cr 16Cr 1.06TCr 16Cr 110.25Cr 43Cr 541.31Cr 42Cr 41Cr 1.76TCr |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COSM Stock
- COSM Stock
Select your edition
All financial news and data tailored to specific country editions
















